Literature DB >> 10948442

The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.

M D Pegram1, G Konecny, D J Slamon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10948442     DOI： 10.1007/978-1-4757-3147-7_4

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  50 in total

Review 1.  Molecular-targeted nanotherapies in cancer: enabling treatment specificity.

Authors:  Elvin Blanco; Angela Hsiao; Guillermo U Ruiz-Esparza; Matthew G Landry; Funda Meric-Bernstam; Mauro Ferrari
Journal:  Mol Oncol       Date:  2011-10-25       Impact factor: 6.603

Review 2.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.

Authors:  E W Duiker; E C F Dijkers; H Lambers Heerspink; S de Jong; A G J van der Zee; P L Jager; J G W Kosterink; E G E de Vries; M N Lub-de Hooge
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

Authors:  Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Javier A Menendez
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

5.  Robust unmixing of tumor states in array comparative genomic hybridization data.

Authors:  David Tolliver; Charalampos Tsourakakis; Ayshwarya Subramanian; Stanley Shackney; Russell Schwartz
Journal:  Bioinformatics       Date:  2010-06-15       Impact factor: 6.937

6.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

7.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Authors:  Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling
Journal:  J Transl Med       Date:  2010-06-07       Impact factor: 5.531

Review 8.  Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models.

Authors:  Christina N Bennett; Jeffrey E Green
Journal:  Breast Cancer Res       Date:  2008-09-11       Impact factor: 6.466

9.  Applying unmixing to gene expression data for tumor phylogeny inference.

Authors:  Russell Schwartz; Stanley E Shackney
Journal:  BMC Bioinformatics       Date:  2010-01-20       Impact factor: 3.169

10.  HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.

Authors:  Eundeok Chang; Anhi Lee; Eunjung Lee; Hekyung Lee; Okran Shin; Sejeong Oh; Changsuk Kang
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.